Results 81 to 90 of about 280,575 (305)

Trastuzumab (Herceptin (R)): Monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation [PDF]

, 2006
Trastuzumab (Herceptin (R)) is a humanized monoclonal antibody that specifically targets HER2/neu (human epidermal growth factor receptor-2) breast cancer cells, which are overexpressed in about 25-30% of breast carcinomas.
Bauerfeind, Ingo, Rückert, Sandra, Lenhard, Miriam, Ditsch, Nina, Kümper, Carolin, Kahlert, Steffen, Friese, Klaus, Untch, Michael   +7 more
core   +1 more source

Risk Prediction Models for Recurrence After Curative Treatment of Early‐Stage or Locally Advanced Lung Cancer: A Systematic Review

Aging and Cancer, EarlyView.
This systematic review synthesizes prognostic models for survival and recurrence in resected non‐small cell lung cancer. While many models demonstrate moderate to good discrimination, few are externally validated and reporting quality is variable, limiting clinical applicability and highlighting the need for robust, transparent model development ...
Evangeline Samuel, S. Tissera, E. Paul, J. Zalcberg, R. G. Stirling   +4 more
wiley   +1 more source

CAR T‐Cell Therapy in Neurology: A Scoping Review of Neuro‐Oncology, Autoimmune Diseases & Neurotoxicity

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Chimeric antigen receptor (CAR) T‐cell therapy has been investigated in neurological diseases, encompassing both central nervous system malignancies and autoimmune disorders, thereby extending its application beyond hematological cancers.
Omar Alqaisi, Mohammed Dibas, Patricia Tai, Ala Dibas, Osama Souied, Suhair Al‐Ghabeesh   +5 more
wiley   +1 more source

Diagnostics and Treatment of Malignant Ovarian Tumors

Southeastern European Medical Journal
Malignant ovarian tumors represent a heterogeneous group of neoplasms and a significant clinical challenge. Due to non-specific symptoms in the early stages, they are often diagnosed late, resulting in poor prognosis.
Ivana Maurac Pašalić, Sara Šota, Miriam Šoletić, Mato Pavić   +3 more
doaj   +1 more source

Neo-adjuvant and adjuvant chemotherapy in bladder cancer

Annals of Oncology, 2007
Transitional cell carcinoma of the bladder represents the second most common genitourinary malignancy [1]; the clinical approach to muscle-invasive disease has been modified in the last decade, considering the important role of multidisciplinary team, including surgeon, oncologist and radiotherapist.
D'AURIA, GIULIANA, CIPROTTI, MARIKA, CONTE, DAVIDE, IACOVELLI, ROBERTO, PALAZZO, ANTONELLA, PELLEGRINO, ARIANNA, CORTESI, Enrico   +6 more
openaire   +2 more sources

Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer

BMC Cancer, 2019
Background Postoperative chemotherapy is beneficial for many pancreatic cancer patients. However, some patients require dose reduction or the discontinuation of adjuvant chemotherapy because of adverse treatment-related effects.
Yoshifumi Morita, Takanori Sakaguchi, Ryo Kitajima, Satoru Furuhashi, Ryota Kiuchi, Makoto Takeda, Takanori Hiraide, Yasushi Shibasaki, Hirotoshi Kikuchi, Hiroyuki Konno, Hiroya Takeuchi   +10 more
doaj   +1 more source

Neo-adjuvant and adjuvant chemotherapy of gastric cancer

Annals of Oncology, 2007
Gastric cancer is still a major health problem and a leading cause of cancer mortality despite a worldwide decline in incidence. Surgery is the primary curative treatment of locoregional gastric cancer. In Western countries, however, at the time of resection, most patients are expected to have regional lymph node involvement with poor prognostic ...
DE VITA, Ferdinando, GIULIANI F, GALIZIA, Gennaro, BELLI C, AURILIO G, SANTABARBARA G, CIARDIELLO, Fortunato, CATALANO G, ORDITURA, Michele   +8 more
openaire   +4 more sources

Efficacy of Adjuvant Chemotherapy and Prognostic Factors for Patients with Extrahepatic Bile Duct Cancer

, 2017
BACKGROUND: Surgical resection is the only curative treatment for extrahepatic bile duct cancer. Additionally, the recurrence rate after curative surgery is relatively high, requiring adjuvant therapy.
박승우, 박정엽, 방승민, 이희승, 정재복, 송시영, 정문재, 이상훈   +7 more
core   +1 more source

Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer [PDF]

, 2007
Background Selective cyclooxygenase inhibitors may retard the progression of cancer, but they have enhanced thrombotic potential. We report on cardiovascular adverse events in patients receiving rofecoxib to reduce rates of recurrence of colorectal ...
Christopher C. McConkey, Justine L. Smith, McConkey, Christopher C., Midgley, RS, Kerr, DJ, Janet A. Dunn, Stokes, JC, Midgley, Rachel, Claire Iveson, McConkey, CC, HASH(0x55a67f94f158), Midgley, Rachel S. J., HASH(0x55a67f45c688), Iveson, Claire, David J. Kerr, Ravi Duvvuri, Iveson, C, Patrick Julier, Julier, P, Smith, JL, Joanne C. Stokes, Langman, Michael J., Julier, Patrick, Duvvuri, Ravi, Rachel S.J. Midgley, Smith, Justine L., Michael J. Langman, Dunn, Janet A., Duvvuri, R, Kerr, David J., Kerr, David, Langman, MJ, Stokes, Joanne C., Andrew Stanley, Stanley, A, Dunn, JA, Stanley, Andrew   +36 more
core   +1 more source

Intrinsic Photoactive Star ZnPc–Poly(glutamate) Nanoplatforms for Multimodal Glioblastoma Therapy and Brain‐Targeted Delivery

Advanced Functional Materials, EarlyView.
An intrinsic photoactive star‐shaped zinc phtalocyanine‐poly(L‐glutamic acid) (ZnPc‐PGA) nanoplatform for multimodal glioblastoma (GBM) therapy and brain‐targeted elivery. A ZnPc‐PGA‐based multifunctional theranostic nanocarrier platform enables image‐guided, multimodal GBM therapy. ZnPc‐PGA nanocarriers support the integration of fluorescence imaging,
Amina Benaicha‐Fernández, Teodora Ranđelović, Ana Armiñán, Víctor Sebastián, Manuel Fuentes, Cristián Huck‐Iriart, Esther Masiá, Paula Carrascosa‐Marco, Pablo Juanes‐Velasco, Snežana Đorđević, Clara Bayona, Ignacio Ochoa, Maria Medel, Inmaculada Conejos‐Sánchez, María J. Vicent   +14 more
wiley   +1 more source